title: Danazol treatment of benign breast disease: a survey of U.S.A. multi-centre studies.
abstract: 514 patients with benign breast disease provided records from multicentre studies in the U.S.A. Results showed that a high proportion responded with either decrease or elimination of symptoms, response usually being apparent 15 to 45 days after commencing treatment. Dosage schedules varied between 50 and 400 mg danazol daily and length of treatment between 15 and 196 days. There was a tendency for patients with more severe symptoms to respond better to the higher dosages, and for the elimination rate for all grades of severity to improve with time. Side effects were not severe, and of the expected type including weight gain, oiliness of skin and hair, and acne.
mesh_terms: D001941:Breast Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003613:Danazol / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008598:Menstruation / Q000187:drug effects; D011245:Pregnadienes / Q000627:therapeutic use*
chemical_list: D011245:Pregnadienes; D003613:Danazol